ClinicalTrials.gg
RecruitingNCT07485452OSIBBBOOSTUpdated Jun 5, 2026

Boosting Osimertinib Blood Brain Barrier Penetration

A Phase 2 interventional study of Osimertinib & febuxostat in Non-Small Cell Lung Cancer, sponsored by Maastricht University Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Maastricht University Medical Center · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
84th of 90
7 · median 51
Started
2026
with 4 others
Phase 2
46 of 90
12 open now
Primary completion
2027-06
later than 24 of 42 live
Registered
88th of 90
by date
Lead sponsor
2 of 90
Maastricht University Medical Center

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 84th largest by planned enrollment, is one of 5 that started in 2026, is one of 46 in phase 2, reaches primary completion later than 24 of the 42 other live ones, and was the 88th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this proof-of-concept clinical study is to determine the effect of combining osimertinib with febuxostat on cerebrospinal fluid concentrations of osimertinib in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). The main question it aims to answer is: what is the effect of combining osimertinib with the ABCG2 inhibitor febuxostat on cerebrospinal fluid to unbound plasma osimertinib concentration ratio in patients with EGFR mutated NSCLC without central nervous system (CNS) metastases and without the ABCG2 34G>A single nucleotide polymorphism (SNP)?

Read the detailed description

One of the preferred first line treatment for metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is osimertinib, a tyrosine kinase inhibitor (TKI). Despite the good intracranial efficacy of osimertinib compared with older-generation EGFR-TKIs, 10-20% of patients develop new or progressing central nervous system (CNS) metastases, the reason for which is unknown. Although the CNS penetration of osimertinib should be sufficient to reach therapeutic concentrations, drug efflux pumps in the blood brain barrier (BBB) could play a role in preventing therapeutic concentrations, especially in patients without baseline CNS metastases. In these patients the BBB is not compromised in contrast to patients with baseline CNS metastases, in whom a leaky BBB allows better penetration of osimertinib. As a result, microscopic CNS metastases then have the opportunity to grow.

Osimertinib is a substrate of drug transporters P-glycoprotein (P-gp; gene: ABCB1) and Breast Cancer Resistance Protein (BCRP) (ABCG2; gene: ABCG2), present in the BBB. Germline variations in these transporters influence intracerebral osimertinib efficacy. Patients without CNS metastases and with the ABCG2 34G>A single nucleotide polymorphism (SNP) have a 72% reduced risk of developing CNS metastases compared to other genotypes, potentially due to diminished osimertinib BBB-efflux, resulting in higher cerebrospinal fluid (CSF) penetration. This finding offers rationale to combine osimertinib with febuxostat, a strong selective ABCG2 transporter inhibitor, in order to enhance the intracerebral osimertinib concentration in patients without the ABCG2 34G>A SNP (\~85% of patients).

The main trial endpoint is the change in the CSF to unbound plasma concentration ratio of osimertinib before and after co-administration with febuxostat.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  1. The patient has EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable disease or better. Patients with (signs of) disease progression, are also eligible if their treating physician deems the treatment to be appropriate beyond progression and the expected osimertinib treatment duration is at least 1 month.
  2. The patient has an European Cooperative Oncology Group () performance status (PS) of 0-2.
  3. The patient is 18 years of age or older.
  4. The patient is able and willing to sign prior to any tests or procedures.
  5. The patient is able and willing to undergo additional blood sampling for e.g. therapeutic drug monitoring.
  6. The patient is able and willing to undergo lumbar punctions to obtain CSF.
  7. The patient must meet the criteria stated in the approved regulatory indication(s) for osimertinib where the clinical study will be performed and agree to the restrictions, monitoring, and dose-adjustment criteria stipulated in the associated product label.
  8. The patient does not harbour the ABCG2 34G>A single nucleotide polymorphism.
  9. The patient does not have any central nervous system (CNS) metastases.
  10. Patients with are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of co-infection or history of HCV co-infection
    • Demonstrated absence of infection
    • Participants with active HBV infection are eligible if they are:
    • Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to \<100 IU/mL and transaminase levels are below .
    • Participants with a resolved or chronic HBV infection are eligible if they are:

      • Negative for HBsAg and positive for hepatitis B core antibody [anti-HBc IgG or total anti-HBc Ab]. In addition, patients should be referred to a local hepatologist and treated as per local guidelines. or
      • Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below \<100 IU/mL or below the detectable limit of locally available test kit (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.
  11. Patients with HIV are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of HBV/ HCV co-infection
    • Undetectable viral RNA load for 6 months
    • of >350 cells/µL
    • No history of AIDS-defining opportunistic infection within the past 12 months
    • Stable for at least 4 weeks on the same anti-HIV medications
  12. Patients must be willing to use protocol specified method of during treatment with osimertinib and 6 weeks tafter the lost dose of osimertinib.

    • Females who are not abstinent (in line with the preferred and usual lifestyle choice of the patient) and intend to be sexually active with a male partner must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

      • defined as aged 50 years or more and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
      • Women under 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution
      • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
    • Male participants must be willing to use barrier contraception

Exclusion criteria

Exclusion criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  1. The patient has an acute gout attack, and medical history of gout or xanthinuria
  2. The patient uses urate-lowering agents, azathioprine, 6-mercaptopurine, tioguanine
  3. The patient uses potent inducers of UDP-glucuronosyltransferase (UGT) enzymes, such as rifampicin and carbamazepine
  4. The patient uses prohibited co-medication: drugs that moderately or strongly inhibits or induces or P-glycoprotein (P-gp)
  5. The patient has received prior treatment with intrathecal chemotherapy
  6. The patient has moderate or severe hepatic dysfunction ( B or C)
  7. The patient has a significantly increased rate of uric acid production (such as in Lesch-Nyhan syndrome)
  8. The patient is pregnant or lactating
  9. The patient has been diagnosed with severe cardiovascular conditions (including history of myocardial infarction, stroke or instable angina pectoris, or congestive heart failure)
  10. Any of the following cardiac criteria:

    • Mean resting interval (QTc) > 470 msec, obtained from 3 (ECGs), using the screening clinic ECG machine derived QTc value.
    • Any abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.
    • Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities including: Hypokalaemia* ≥ Grade 2 (*correction of electrolyte abnormalities should be documented prior to first dose), heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes.
  11. Creatinine >1.5 times concurrent with \<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN
  12. Known galactose-intolerance, Lapp lactasedeficiency or glucose-galactose malabsorption
  13. Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)
  14. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
  15. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection (e.g. patients receiving treatment for infection) including and (HIV), or active uncontrolled infection.

    o Screening for chronic conditions is not required.

  16. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  17. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease.
  18. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • Bone marrow reserve (the use of granulocyte colony stimulating factor support, transfusion and blood transfusions to meet these criteria is not permitted):

      • \<1.5 x 109/L
      • Platelet count \<100 x 109/L
      • \<90 g/L
    • Hepatic function

      • >2.5 times the upper limit of normal (ULN) if no demonstrable liver or >5 times ULN in the presence of liver metastases
      • Aspartate aminotransferase >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
      • Total >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases
  19. History of to active or inactive of osimertinib or febuxostat, or drugs with a similar chemical structure or class to osimertinib or febuxostat.
  20. Osimertinib dosage of less than 80 mg once daily.
  21. Any concurrent and/or other active that has required systemic treatment within 2 years of first dose of osimertinib.
  22. Major surgery within 4 weeks of the first dose of IP. Procedures such as placement of vascular access, via mediastinoscopy or biopsy via video assisted thoracoscopic surgery (VATS) are permitted.
  23. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.
  24. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  25. Participation in another clinical study with an product during the 4 weeks prior to Day 1. Patients in the follow-up period of an interventional study are permitted.
  26. If a patient uses anticoagulants and the treating physician deems it unsafe or not feasible to temporarily interrupt this medication or to bridge oral anticoagulants with parenteral anticoagulation (i.e. LMWH) at the time of the lumbar puncture procedure, the patient will be excluded.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    Combining osimertinib with febuxostat on cerebrospinal fluid concentration of osimertinib

    Determining the effect of combining osimertinib with ABCG2 inhibitor febuxostat on cerebrospinal fluid to unbound plasma osimertinib concentration ratio, in patients with EGFR mutated NSCLC without CNS metastases and without the ABCG2 34G\>A SNP

    Drug: Osimertinib & febuxostat

Interventions

06

What researchers measure

Primary outcomes

  1. Effect of combining osimertinib with febuxostat on osimertinib CSF:plasma ratio in patients with EGFR NSCLC without CNS metastases

    Determining the effect of combining osimertinib with the ABCG2 inhibitor febuxostat on osimertinib cerebrospinal fluid to plasma (CSF:plasma) concentration ratio, in patients with EGFR mutated NSCLC without central nervous system (CNS) metastases on brain MRI. Both CSF and plasma concentrations will be measured before and after combination of osimertinib with febuxostat.

    Time frame: 22-25 days after start of combination osimertinib + febuxostat

Secondary outcomes

  1. Effect on intracerebral osimertinib concentrations after combination with febuxostat

    Evaluating the extent by which febuxostat increases intracerebral osimertinib concentrations, by measuring osimertinib concentration in CSF before and after combination with febuxostat

    Time frame: 22-25 days after start of concurrent treatment

  2. Effect on osimertinib plasma concentrations

    Assessing the effect of febuxostat on osimertinib plasma trough concentration in steady-state, by comparing concentrations before and after combination with febuxostat

    Time frame: 22-25 days after start of combined treatment

  3. Plasma concentrations of AZ5104 and AZ7550

    Assessing the effect of febuxostat on AZ5104 and AZ7550 (i.e. active metabolites of osimertinib) steady-state trough concentrations, by comparing concentrations before and after combined use.

    Time frame: 22-25 days after start of combined treatment

  4. CSF concentrations of AZ5104 and AZ7550

    Assessing the effect of febuxostat on AZ5104 and AZ7550 (i.e. active metabolites of osimertinib) concentrations in CSF, by comparing concentrations before and after combined use.

    Time frame: 22-25 days after start of combined treatment

  5. Tolerability of osimertinib in combination with febuxostat

    Determining tolerability of osimertinib combined with febuxostat, by assessing adverse events according to CTCAE v5.0 criteria

    Time frame: 22-25 days after start of combined treatment

Other outcomes

  1. Effect ABCB1 and ABCG2 genotypes on osimertinib CNS exposure

    Exploring potential effects of different ABCB1 and ABCG2 genotypes on CNS exposure of osimertinib and active metabolites AZ5104 and AZ7550 before and during combination with febuxostat. Therefore, it will be assessed whether variations in osimertinib concentrations (and concentrations of active metabolites) before and during combination with febuxostat may be explained by different ABCB1 and ABCG2 genotypes.

    Time frame: 22-25 days after start combined therapy

  2. Correlation between safety and osimertinib, AZ5104 and AZ7550 concentrations in blood and CSF

    Exploring potential correlations between safety (AEs according to CTCAE v5.0) and osimertinib, AZ5104 and AZ7550 concentrations in blood and CSF

    Time frame: 22-25 days after start combination treatment

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Planchard D, Janne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. PubMed 37937763 ↗
  • Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, Mathijssen RHJ. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine. 2023 Apr 13;59:101955. doi: 10.1016/j.eclinm.2023.101955. eCollection 2023 May. PubMed 37125403 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 12 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Mar 20, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485452
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jun 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Osimertinib · Febuxostat

Start the discussion